SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending amid escalating geopolitical tensions in the Middle East, triggered by drone strikes on oil facilities and disrupted shipping in the Strait of Hormuz that are pushing up energy prices. The community is actively discussing a potential massive short squeeze and parabolic run for this low-float oil stock, drawing comparisons to previous energy crises and expecting significant upside.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending after announcing a $10M strategic investment and partnership with World View to develop layered ISR solutions combining high-altitude balloons and drones. This news is fueling significant community discussion around the stock's substantial short interest and potential for a squeeze, amid broader geopolitical tensions driving demand for advanced defense technology.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid escalating geopolitical tensions, driving intense community discussion around its attack-capable drones and their relevance to modern warfare. Investors are closely watching its participation in the Drone Dominance Program and anticipating updates from its upcoming Innovation Day.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to NVIDIA's increasing focus on photonics for AI data centers, amplifying discussions around POET's disruptive optical interconnect technology. The community is actively debating its potential for significant hyperscaler partnerships and a strong revenue ramp, with many anticipating pivotal announcements leading up to the OFC conference.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Escalating Middle East tensions, including a reported drone strike on Saudi Arabia's largest oil refinery and threats of closure for the Strait of Hormuz, are driving a surge in Battalion Oil Corp. The community is actively discussing the potential for a significant short squeeze and continued upward momentum for BATL and other low-float energy stocks amid rising crude prices.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending amid intensifying Middle East geopolitical tensions, with discussions centered on potential Strait of Hormuz disruptions and Qatar's LNG plant shutdown, leading many to view the integrated energy giant as a direct beneficiary of surging oil and natural gas prices.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending following its new multi-year U.S. brewing and distribution partnership with Carlsberg Group, generating mixed community reactions as some see it as a significant diversification, while others remain highly critical, demanding focus on U.S. cannabis reform and citing concerns over market manipulation and leadership.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging after a strong Q4 earnings report and positive outlook, coming amidst escalating geopolitical tensions in the Middle East and Strait of Hormuz that are tightening global LNG supply. The community is discussing the company's favorable position as a key U.S. LNG exporter and the potential for a significant short squeeze.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending as community discussion vigorously debates the recent US military strikes in Iran, with supporters hailing President Trump's decisive action against perceived threats, while critics allege it is an "illegal war" and a distraction from controversies like the "Epstein files."

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is surging on a significant earnings beat and robust guidance for 800G/1.6T transceivers, driven by strong hyperscale data center demand and analyst upgrades within the burgeoning AI and photonics sector. The community is actively debating its valuation and future growth prospects against concerns over execution risk and potential dilution from a recent stock offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GSA Capital Partners LLP Trims Stock Position in Praxis Precision Medicines, Inc. $PRAX

GSA Capital Partners LLP cut its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 52.2% during the 3rd quarter, according to its most recent 13F filing with the Securities...

Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Wolfe Research

Wolfe Research raised shares of Praxis Precision Medicines to a "strong-buy" rating in a report on Monday...

3,826 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by ProShare Advisors LLC

ProShare Advisors LLC acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the third quarter, according to the company in its most recent disclosure with the...

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year

Key PointsBaker Bros. Advisors LP added 437,000 shares of Praxis Precision Medicines in the fourth quarter; the estimated transaction value is $81.38 million based on quarterly average pricing...

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

Key PointsPerceptive Advisors purchased 431,432 Praxis Precision Medicines shares in the fourth quarter; the estimated trade size was $80.34 million (based on the mean unadjusted close for the...

<ul class="summary-bullets"><li>Truist raised the firm's price target on Praxis Precision to $700 from $500 and maintained a ‘Buy’ rating on the shares.</li><li>Wells Fargo said it is surprised that priority review wasn't requested for Ulixadolid given the drug's Breakthrough Therapy Designation.</li><li>Wedbush continues to hold reservations on the ulixacaltamide filing.</li></ul><p><br>Shares of Praxis Precision Medicines, Inc. (PRAX) rallied 2% on Friday after analysts hiked their price targets on the stock, one as much as $700. The hikes come amid optimism spurred by the company’s recent submissions to the U.S. Food and Drug Administration.</p><p>Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of the neurodevelopmental disorder called Developmental and Epileptic Encephalopathy. Both the experimental drugs were previously granted the Breakthrough Therapy Designation by the FDA.</p><p>“Pending their expected positive reviews, we will be positioned to transition into a commercial company,” said Praxis CEO Marcio Souza. “The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years. Together, these four assets have a revenue potential of over $20 billion.”</p><h2 class="st-heading-2">Analysts React</h2><p>Subsequently, Wedbush raised the firm's price target on Praxis Precision to $130 from $95 and kept an ‘Underperform’ rating on the shares, according to TheFly. The firm said that the most notable in the Q4 2025 update was that management completed submissions for both ulixacaltamide and relutrigine. Acceptance of the application likely arrives mid-April, while management requested priority review solely for relutrigine, not ulixacaltamide, the firm noted. Wedbush continues to hold reservations on the ulixacaltamide filing.</p><p>Wells Fargo, meanwhile, raised the firm's price target on Praxis Precision to $305 from $282 and kept an ‘Equal Weight’ rating on the shares. The firm recently initiated coverage with the view that risk/reward is balanced heading into the Ulixadolid FDA review. It further added that it is surprised that priority review wasn't requested given the drug's Breakthrough Therapy Designation.</p><p>Truist, meanwhile, raised the firm's price target on Praxis Precision to $700 from $500 and maintained a ‘Buy’ rating on the shares. The company's Q4 update was "notable" for its completed NDA submissions, the analyst told investors in a research note.</p><h2 class="st-heading-2">Praxis’ Financial Position</h2><p>On Thursday, Praxis reported net loss per share of $3.5 for the fourth quarter (Q4), compared to an analyst estimate of $3.1</p><p>The company ended 2025 with $926.1 million in cash, cash equivalents and marketable securities. This, coupled with the $621.2 proceeds from a Jan. 2026 follow-on public offering, are expected to fund operations into 2028, the company said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around PRAX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</p><p>According to data from Koyfin, the average 12-month price target on the stock is $599.94, representing a potential upside of about 81% from the last closing price.</p><p><a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> has more than quadrupled in value over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-inks-partnerships-to-launch-cancer-drug-in-saudi-arabia/cZRNf8cR4xF">ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock

Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of Developmental and Epileptic Encephalopathy.

Equity

Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of Developmental and Epileptic Encephalopathy.


Praxis Precision Medicines (NASDAQ:PRAX) Sets New 1-Year High Following Analyst Upgrade

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 1-Year High on Analyst Upgrade...

Truist Financial Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock

Truist Financial raised their price target on Praxis Precision Medicines from $500.00 to $700.00 and gave the company a "buy" rating in a report on Friday...

Praxis Precision Medicines (NASDAQ:PRAX) Posts Earnings Results, Misses Estimates By $0.50 EPS

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) announced its earnings results on Thursday. The company reported ($3.50) earnings per share for the quarter, missing the consensus estimate...

Praxis Precision Medicines Q4 Earnings Call Highlights

Praxis Precision Medicines (NASDAQ:PRAX) used its fourth-quarter and full-year 2025 earnings call to highlight multiple regulatory and clinical milestones across its central nervous system portfolio...

Praxis Precision Medicines Inc

TD Cowen 46th Annual Health Care Conference

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Current Price	$330.74
Prev Close	$336.75
Open	$334.03
Dividend Yield	0.00%
50-Day Moving Average	$305.11
Beta	0.50
Avg. Volume	598,381.45
PE Ratio	-25.01

52-Week High	$356.00
52-Week Low	$26.70
Market Capitalization	$9.38B
EPS (Annual)	-$13.48
Price to Book	9.66
Revenue Per Employee	$0.00

PRAX
Praxis Precision Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRAX News

PRAXPraxis Precision Medicines Inc